Fear conditioning and extinction are well-characterized cross-species models of fear-related posttraumatic stress disorder (PTSD) symptoms, and recent animal data suggest that 3,4-methylenedioxymethamphetamine (MDMA) enhances fear extinction retention.
Aims:
This study investigated the effect of MDMA on fear learning, extinction training, and retention in healthy humans.
Methods:
The study involved a randomized placebo-controlled, two-group, parallel design trial in a sample of healthy adults, age 21–55 recruited from a major metropolitan area. The experimental paradigm included a fear acquisition session followed by an extinction training session 24 hours later, and 2 hours after study drug administration. Fear extinction retention was measured 48 hours after extinction training. Participants (N = 34; 70.6% male and 29.4% female) were randomly assigned in 1:1 ratio to 100 mg MDMA or placebo. All randomized participants completed the trial and were included in primary analyses. Safety was monitored via adverse events and vital signs. MDMA was well-tolerated with no serious adverse events.
Results:
Results indicated a significant main effect of session between extinction training and retention with no significant group differences. Significantly more participants in the MDMA group retained extinction learning compared to the placebo group (χ2 = 7.29, p = 0.007).
Conclusion:
Although we did not observe the hypothesized facilitation of extinction retention, the findings from this initial human trial provide compelling rationale to continue to explore the potential for MDMA to impact extinction retention.
American Psychological Association (2017) Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults. Washington, DC: American Psychological Association.
2.
BediGHymanDde WitH (2010) Is ecstasy an “empathogen”? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biological Psychiatry68: 1134–1140.
3.
BershadAKMillerMABaggottMJ, et al. (2016) The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?Journal of Psychopharmacology30: 1248–1258.
4.
BoutonMEVurbicDWoodsAM (2008) D-cycloserine facilitates context-specific fear extinction learning. Neurobiology of Learning and Memory90(3): 504–510.
5.
BradleyRGreeneJRussE, et al. (2005) A multidimensional meta-analysis of psychotherapy for PTSD. American Journal of Psychiatry162(2): 214–227.
6.
BriscioneMAJovanovicTNorrholmSD (2014) Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors. Frontiers in Psychiatry5: 88.
7.
BrownLALeBeauRTChatK-Y, et al. (2017) Associative learning versus fear habituation as predictors of long-term extinction retention. Cognition and Emotion31(4): 687–698.
8.
Carhart-HarrisRLMurphyKLeechR, et al. (2015) The effects of acutely administered 3, 4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level–dependent resting state functional connectivity. Biological Psychiatry78(8): 554–562.
9.
CusackKJonasDEFornerisCA, et al. (2016) Psychological treatments for adults with posttraumatic stress disorder: A systematic review and meta-analysis. Clinical Psychology Review43: 128–141.
10.
De la TorreRFarreMRosetPN, et al. (2000) Pharmacology of MDMA in humans. Annals of the New York Academy of Sciences914(1): 225–237.
11.
FarréMAbanadesSRosetPN, et al. (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics323(3): 954–962.
12.
FeducciaAAMithoeferMC (2018) MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?Progress in Neuro-Psychopharmacology and Biological Psychiatry84: 221–228.
13.
FeducciaAAJeromeLKlosinskiB, et al. (2019) Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Frontiers in Psychiatry10: 650.
14.
GloverEMJovanovicTNorrholmSD (2015) Estrogen and extinction of fear memories: Implications for posttraumatic stress disorder treatment. Biological Psychiatry78(3): 178–185.
15.
HakeHSDavisJKWoodRR, et al. (2019) 3, 4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiology & Behavior199: 343–350.
16.
HarrisDSBaggottMMendelsonJH, et al. (2002) Subjective and hormonal effects of 3, 4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology162(4): 396–405.
17.
HolzeFVizeliPMullerF, et al. (2020) Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology45: 462–471.
18.
HysekCMSchmidYSimmlerLD, et al. (2014a) MDMA enhances emotional empathy and prosocial behavior. Social Cognitive and Affective Neuroscience9: 1645–1652.
19.
HysekCMSimmlerLDSchillingerN, et al. (2014b) Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination. International Journal of Neuropsychopharmacology17: 371–381.
20.
Institute of Medicine (US). Committee on Treatment of Posttraumatic Stress Disorder (2007) Treatment of posttraumatic stress disorder: An assessment of the evidence. In Institute of Medicine (Eds.), Appendix D, Analysis and Interpretation of Studies with Missing Data, Washington, DC: Institute of Medicine, pp. 185–194.
21.
JeromeLFeducciaAAWangJB, et al. (2020) Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology237: 2485–2497.
22.
JovanovicTNorrholmSD (2011) Neural mechanisms of impaired fear inhibition in posttraumatic stress disorder. Frontiers in Behavioral Neuroscience5: 44.
23.
JovanovicTKazamaABachevalierJ, et al. (2012) Impaired safety signal learning may be a biomarker of PTSD. Neuropharmacology62(2): 695–704.
24.
JovanovicTNorrholmSDFennellJE, et al. (2009) Posttraumatic stress disorder may be associated with impaired fear inhibition: Relation to symptom severity. Psychiatry Research167(1–2): 151–160.
25.
KesslerRC (2000) Posttraumatic stress disorder: The burden to the individual and to society. The Journal of Clinical Psychiatry61: 4–14.
26.
Maples-KellerJLRauchSAJovanovicT, et al. (2019) Changes in trauma-potentiated startle, skin conductance, and heart rate within prolonged exposure therapy for PTSD in high and low treatment responders. Journal of Anxiety Disorders68: 102147.
27.
MiladMRQuirkGJ (2012) Fear extinction as a model for translational neuroscience: Ten years of progress. Annual Review of Psychology63: 129–151.
28.
MiladMRWrightCIOrrSP, et al. (2007) Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biological Psychiatry62(5): 446–454.
29.
MitchellJMBogenschutzMLiliensteinA, et al. (2021) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine27(6): 1025–1033.
30.
MithoeferMCFeducciaAAJeromeL, et al. (2019) MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology236(9): 2735–2745.
31.
MithoeferMCMithoeferATFeducciaAA, et al. (2018) 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry5(6): 486–497.
32.
MyersKMDavisM (2002) Behavioral and neural analysis of extinction. Neuron36(4): 567–584.
33.
NorrholmSDJovanovicTGerardiM, et al. (2016) Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy. Behaviour Research and Therapy82: 28–37.
34.
NorrholmSDJovanovicTOlinIW, et al. (2011) Fear extinction in traumatized civilians with posttraumatic stress disorder: Relation to symptom severity. Biological Psychiatry69(6): 556–563.
35.
NorrholmSDJovanovicTVervlietB, et al. (2006) Conditioned fear extinction and reinstatement in a human fear-potentiated startle paradigm. Learning & Memory13(6): 681–685.
36.
NorrholmSDVervlietBJovanovicT, et al. (2008) Timing of extinction relative to acquisition: A parametric analysis of fear extinction in humans. Behavioral Neuroscience122(5): 1016.
37.
OehenPTraberRWidmerV, et al. (2013) A randomized, controlled pilot study of MDMA (±3, 4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Journal of Psychopharmacology27(1): 40–52.
38.
ReiffCMRichmanEENemeroffCB, et al. (2020) Psychedelics and psychedelic-assisted psychotherapy. AMerican Journal of Psychiatry177(5): 391–410.
39.
Robison-AndrewEJDuvalERNelsonCB, et al. (2014) Changes in trauma-potentiated startle with treatment of posttraumatic stress disorder in combat Veterans. Journal of Anxiety Disorders28(4): 358–362.
40.
RothbaumBODavisM (2003) Applying learning principles to the treatment of post-trauma reactions. Annals of the New York Academy of Sciences1008(1): 112–121.
41.
RothbaumBOFoaEBRiggsDS, et al. (1992) A prospective examination of post-traumatic stress disorder in rape victims. Journal of Traumatic Stress5(3): 455–475.
42.
RothbaumBOPriceMJovanovicT, et al. (2014) A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. American Journal of Psychiatry171(6): 640–648.
43.
SchmidYHysekCMSimmlerLD, et al. (2014) Differential effects of MDMA and methylphenidate on social cognition. Journal of Psychopharmacology28: 847–856.
44.
SessaB (2017) MDMA and PTSD treatment: “PTSD: From novel pathophysiology to innovative therapeutics.”Neuroscience Letters649: 176–180.
45.
SheehanDVLecrubierYSheehanKH, et al. (1998) The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry59(20): 22–33.
46.
ShumakeJJonesCAuchterA, et al. (2018) Data-driven criteria to assess fear remission and phenotypic variability of extinction in rats. Philosophical Transactions of the Royal Society B: Biological Sciences373(1742): 20170035.
VizeliPLiechtiME (2017) Safety pharmacology of acute MDMA administration in healthy subjects. Journal of Psychopharmacology31(5): 576–588.
49.
WarrenVTAndersonKMKwonC, et al. (2014) Human fear extinction and return of fear using reconsolidation update mechanisms: The contribution of on-line expectancy ratings. Neurobiology of Learning and Memory113: 165–173.
50.
YoungMBAnderoRResslerKJ, et al. (2015) 3, 4-Methylenedioxymethamphetamine facilitates fear extinction learning. Translational Psychiatry5: e634.
51.
YoungMBNorrholmSDKhouryLM, et al. (2017) Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3, 4-methylenedioxymethamphetamine (MDMA). Psychopharmacology234(19): 2883–2895.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
